Navigation Links
Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors at AACR-NCI-EORTC International Conference
Date:10/24/2007

- favorable pharmacokinetic and safety data observed in first clinical

trial of novel Fleximer(TM) anticancer agent -

CAMBRIDGE, Mass., Oct. 24 /PRNewswire/ -- Mersana, a cancer therapeutics company, announced interim results of a Phase I study of its lead product candidate, XMT-1001, in patients with advanced solid tumors. The data was presented by Edward A. Sausville, M.D., Ph.D, Professor of Medicine and Associate Director for Clinical Research, University of Maryland Greenebaum Cancer Center in a poster session on October 23 at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Therapeutics taking place in San Francisco, CA. Full text of the abstract #A146 "A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients with Advanced Solid Tumors" can be viewed online at the AACR website at http://www.aacr.org. XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity.

Commenting on the data, Robert J. Fram, M.D. Chief Medical Officer at Mersana, stated: "The Phase I results show that, in humans, camptothecin, the active agent in XMT-1001, is released gradually from the Fleximer carrier as a pro-drug in a manner that will potentially avoid common safety problems associated with drugs in this class. To date, we've seen no evidence of drug-related serious adverse events and the study is ongoing."

Results were presented from 12 patients enrolled in an ongoing Phase I open-label, dose-escalation trial designed to determine the safety, tolerability and pharmacokinetic profile of XMT-1001. To date, XMT-1001 has been well tolerated in patients and no serious drug related adverse events have been reported. Preliminary results demonstrate a favorable pharmacokinetic profile with low levels of CPT, both total and free, recovered in urine. The ma
'/>"/>

SOURCE Mersana Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...re/--Reportlinker.comannouncesthatanewmarketresear...alDrugDelivery-USMarketTrends&Analysis http:/...ivery---US-Market-Trends--Analysis.html ,, The...ionoftherapeuticapplicationsfromthedeliveryofconve...ctherapeuticdrugs.Thefutureofthetechnologyhingeson...
(Date:11/25/2009)....25/PRNewswire/-- ChemoCentryx,Inc.,announcedtoda...T-1(theProspectiveRandomizedOralTherapyEvaluationi...patientswithmoderate-to-severeCrohn,sdiseasedemons...abilityprofile.Thestudydemonstratedevidenceofclini...dasa70-pointdecreaseintheCrohn,sDiseaseActivityInd...
(Date:11/24/2009)...Newswire-FirstCall/--Endologix,Inc.(Nasdaq: ELGX )...sorders,announcedtodaythatithasfiledamotiontostay,...tlawsuitbroughtagainstitinOctober2009byCook,Inc.Th...ianapolis,Indiana. ,, Endologixhasrequestedthat...TrademarkOffice(USPTO)conductsproceedingstore-exam...
Breaking Medicine Technology:Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2First Annual Conference of National Association of Healthcare Advocacy Consultants 28NAHAC 29 to Be Held Nov 14 15 3B Board of Directors Announced 59341 1First Annual Conference of National Association of Healthcare Advocacy Consultants 28NAHAC 29 to Be Held Nov 14 15 3B Board of Directors Announced 59341 2The Governator and the Disintegrator 3A A Sharp Match Holding Pharmaceutical Companies Accountable 5416 1The Governator and the Disintegrator 3A A Sharp Match Holding Pharmaceutical Companies Accountable 5416 2The Governator and the Disintegrator 3A A Sharp Match Holding Pharmaceutical Companies Accountable 5416 3Vivacare Delivers Medication Information to Patients through Doctor Websites 59336 1Vivacare Delivers Medication Information to Patients through Doctor Websites 59336 2Vivacare Delivers Medication Information to Patients through Doctor Websites 59336 3
...re-FirstCall/ -- Amylin,Pharmaceuticals, Inc. toda...tes drugs, BYETTA(R) (exenatide) injection and,SYM...peline,candidates will be presented at the America...fic Sessions being held in Chicago, IL,from June 2...esentation during the meeting that will be availab...
...20, 2007 - Neoprobe Corporation,(OTCBB:NEOP), a di...diovascular surgical and diagnostic products, toda...lticenter Phase 2 clinical,study of its lead clini...A-mannosyl-dextran). Lymphoseek is a proprietary,r... with handheld,gamma detection devices, such as Ne...
Other Medicine Technology:Amylin Pharmaceuticals to Present New Data from Broad Diabetes and,Obesity Programs at ADA 2007 2Amylin Pharmaceuticals to Present New Data from Broad Diabetes and,Obesity Programs at ADA 2007 3Amylin Pharmaceuticals to Present New Data from Broad Diabetes and,Obesity Programs at ADA 2007 4Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint 2Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint 3
(Date:11/26/2009)...ge that,s too big or too heavy can lead to strains...ay News) -- There may be nothing wrong with stuffi... want to do the same thing with your suitcase as y...eople were treated in 2008 in U.S. hospital emerge...ical facilities for luggage-related injuries, such...
(Date:11/26/2009)... Dr. David Kim of the Live Lif...urgery in Dallas , is one of a growing number of p...ial networking sites to connect with individuals w...t to fight morbid obesity. Dr. Kim is utilizing Fa...ation about his practice with the community. , ...
(Date:11/26/2009)... Ennis & Ennis, P.A. is of...for users of Yaz and Yasmin birth control pills wh...onary Embolism, Stroke, Heart Attack or other rela...d. Women can call toll free at 1-800-856-6405 or g...law.com and fill out an online case evaluation fo...
(Date:11/25/2009)..., EMERYVILLE,Calif.,Nov.25/PRNewswire-FirstCall/-...ouncedthatthecompanywillhosttwoinvestoreventsinDec...9-9:00a.m.CT/10:00a.m.ET ,, Principalinvestig...zomibinrelapsedand/orrefractorymultiplemyeloma,asf...nualMeetingandExpositioninNewOrleans,LA.Thetelecon...
(Date:11/25/2009)..., LONGBEACH,Calif.,Nov.25/PRNewswire/--Thanksgivi...dseniorsinthegreaterLongBeachareathankstoFaithInAc...ependenceatHome(IAH),adivisionofSCANHealthPlan.For...edsofvolunteerstodeliverwarmThanksgivingmealstosen...,SouthLosAngelesandsurroundingcities. ,, "Ourwa...
Breaking Medicine News(10 mins):Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2
...facturing, explores industry trends and the utili...ATLANTA, Sept. 13 Visiprise, Inc., a leader in,ma...grated enterprise,announced today that the company...cturing," these free, online podcasts,will include...
...Stop Stroke, ZURICH, Switzerland, Sept. 13 Thirt...Switzerland used a small tube with a tiny,balloon ... patient,s,blocked heart artery. The procedure, c... marked a breakthrough that, three decades later, ...
...Disability (NCD) today urged Congress to support l...ricans with Disabilities Act (ADA) and protect,the...storation bills were introduced in the House (H.R....entation, effectiveness, and impact of the ADA. In...
...rstCall/ -- China,Shenghuo Pharmaceutical Holdings...UN ), which is engaged in the research, developmen...tritional supplement and cosmetic,products in the ...nday, September 9, 2007. "We are excited about th...
...c.,(Scimitar) today issued a review on Arbios Syst...hancing the Recovery of Patients with Life,Threate...rch review is,available on Scimitar,s website: ht...ng microporous hollow fibers with proprietary perm...
...ubling as blood cells decline , THURSDAY, Sept. 13...clining blood platelet counts may be at increased ...umber of cognitive, behavioral and motor skill pro...ied 396 patients with advanced HIV disease. Betwee...
Other Medicine News:Health News:Visiprise Launches Podcast Series with AMR to Support Medical Device Manufacturers 2Health News:On 30th Anniversary, Angioplasty Celebrated as Modern Medical Breakthrough in Stopping Heart Attack 2Health News:On 30th Anniversary, Angioplasty Celebrated as Modern Medical Breakthrough in Stopping Heart Attack 3Health News:On 30th Anniversary, Angioplasty Celebrated as Modern Medical Breakthrough in Stopping Heart Attack 4Health News:On 30th Anniversary, Angioplasty Celebrated as Modern Medical Breakthrough in Stopping Heart Attack 5Health News:National Council on Disability Urges Congress to Support Americans with Disabilities Act Restoration 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line 3Health News:China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line 4Health News:Arbios Systems, Inc's Q2/07 Analyst Review Issued by Scimitar Equity Research, Inc. 2Health News:Falling Platelet Counts May Signal HIV-Linked Dementia 2
Steel Knife with box, D-Profile
...k that is revolutionary, a feel that is marvelous,...ll please the most demanding of users. Based on y...g new ground with an innovative design the SureCut...r laboratory cutting and sectioning needs.,NE...
Feather Disposable Blades, Pack of 50
SureCut M3500 Fine Thread Conversion Kit
Medicine Products: